Compare
Lifecore Biomedical, Inc. vs UroGen Pharma Ltd. vs Zevra Therapeutics, Inc. vs Phathom Pharmaceuticals, Inc.
| Latest fiscal year | Lifecore Biomedical, Inc. LFCR | UroGen Pharma Ltd. URGN | Zevra Therapeutics, Inc. ZVRA | Phathom Pharmaceuticals, Inc. PHAT |
|---|---|---|---|---|
| Year ended | 2025-05-25 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $128.87M | $109.79M | $106.47M | $175.11M |
| Revenue growth (YoY) | +0.5% | +21.4% | +350.9% | +216.9% |
| Gross margin | 31.3% | 88.7% | n/a | 87.1% |
| Operating margin | -13.4% | -113.7% | -59.1% | -91.4% |
| Net margin | -30.0% | -139.8% | 78.2% | -126.3% |
| Net income | -$38.72M | -$153.49M | $83.23M | -$221.25M |
| EPS (Diluted) | -$1.27 | n/a | $1.35 | -$3.03 |
| Operating cash flow | -$206.0K | -$162.44M | -$1.60M | -$166.78M |
| Free cash flow | -$13.62M | -$162.73M | -$2.43M | -$167.00M |
| Cash & equivalents | $8.27M | $110.75M | $62.41M | $129.97M |
| Total assets | $239.34M | $200.46M | $284.73M | $259.15M |
| Total liabilities | $191.91M | $305.93M | $130.07M | $697.32M |
| Shareholders' equity | $1.34M | -$105.47M | $154.66M | -$438.17M |
| Return on year-end equity | n/m | n/a | 53.8% | n/a |
| Shares outstanding | 37.03M | 48.35M | 56.85M | 71.42M |
Revenue, most recent five fiscal years
| Fiscal year | Lifecore Biomedical, Inc. | UroGen Pharma Ltd. | Zevra Therapeutics, Inc. | Phathom Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $128.87M Ended 2025-05-25 | $109.79M Ended 2025-12-31 | $106.47M Ended 2025-12-31 | $175.11M Ended 2025-12-31 |
| 1 year earlier | $128.26M Ended 2024-05-26 | $90.40M Ended 2024-12-31 | $23.61M Ended 2024-12-31 | $55.25M Ended 2024-12-31 |
| 2 years earlier | $103.27M Ended 2023-05-28 | $82.71M Ended 2023-12-31 | $27.46M Ended 2023-12-31 | $682.0K Ended 2023-12-31 |
| 3 years earlier | $111.27M Ended 2022-05-29 | $64.36M Ended 2022-12-31 | $10.16M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $100.87M Ended 2021-05-30 | $48.04M Ended 2021-12-31 | $28.65M Ended 2021-12-31 | n/a |